Olayinka Sunday Okoh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Olayinka Sunday Okoh has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Nidia Sequeira Trovao
Department of Pathobiology, College of Veterinary Medicine, University of Illinois Urbana-Champaign, Urbana, IL 61802, USA
3 shared publications - Amina Jega Yusuf
Department of Pharmaceutical and Medicinal Chemistry, Usmanu Danfodiyo University, Sokoto, Nigeria
2 shared publications Anna Aba Kafintu-Kwashie
Department of Medical Microbiology, Clinical Virology Unit, University of Ghana Medical School, Accra, Ghana
2 shared publications- Elijah Kolawole Oladipo
Division of Genome and Molecular Sciences, Helix Biogen Institute, Ogbomoso, Nigeria
2 shared publications Ifiokakaninyene Ekpo Akaninyene
Department of Pure and Applied Biology (Microbiology Unit), Ladoke Akintola University of Technology, Ogbomoso, Nigeria
2 shared publicationsMichael Asebake Ockiya
Department of Animal Science, Niger Delta University, Wilberforce Island, Bayelsa, Nigeria
2 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (11) , e0361047
Anti-inflammatory effects of metformin in gestational diabetes: Systematic review and meta-analysis of randomized trials and preclinical animal pregnancy models study protocol
Background: Gestational diabetes mellitus (GDM) is a significant complication that can occur during pregnancy. It is characterized by glucose intolerance that first arises during pregnancy and is associated with insulin resistance, which is linked to elevated inflammatory markers. Metformin has emerged as a promising treatment option for GDM, with growing evidence supporting its anti-inflammatory effects. These effects are thought to be mediated by activation of AMP-activated protein kinase (AMPK) and inhibition of NF-κB signaling. This systematic review aims to assess the anti-inflammatory effects of metformin in GDM, considering both clinical and preclinical studies. Methods: A systematic review of all randomized controlled trials and controlled in vivo experiments for animals published until 2026 will be carried out. A comprehensive search of all published articles indexed in PubMed/MEDLINE, the Cochrane Library, Scopus, CINAHL (EBSCOhost), Embase, and Web of Science will be performed. Studies will be screened for eligibility by title, abstract, and full text in duplicate by two independent reviewers. For data where meta-analysis is not possible, a narrative analysis will be conducted using themes derived from the data. For data that allow meta-analysis, a random-effects meta-analysis will be conducted. This systematic review will be reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). Discussion: The study will utilize meta-analysis to establish the anti-inflammatory effects of metformin in GDM, potentially influencing clinical practice and guidelines. Additionally, validating metformin’s anti-inflammatory effects has important implications beyond immediate management of GDM, extending to long-term adverse outcomes for both the mother and the offspring. Systematic review registration: PROSPERO CRD420261337881
- 12 November 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (11) , e0361047
Open AccessAnti-inflammatory effects of metformin in gestational diabetes: Systematic review and meta-analysis of randomized trials and preclinical animal pregnancy models study protocol
Background: Gestational diabetes mellitus (GDM) is a significant complication that can occur during pregnancy. It is characterized by glucose intolerance that first arises during pregnancy and is associated with insulin resistance, which is linked to elevated inflammatory markers. Metformin has emerged as a promising treatment option for GDM, with growing evidence supporting its anti-inflammatory effects. These effects are thought to be mediated by activation of AMP-activated protein kinase (AMPK) and inhibition of NF-κB signaling. This systematic review aims to assess the anti-inflammatory effects of metformin in GDM, considering both clinical and preclinical studies. Methods: A systematic review of all randomized controlled trials and controlled in vivo experiments for animals published until 2026 will be carried out. A comprehensive search of all published articles indexed in PubMed/MEDLINE, the Cochrane Library, Scopus, CINAHL (EBSCOhost), Embase, and Web of Science will be performed. Studies will be screened for eligibility by title, abstract, and full text in duplicate by two independent reviewers. For data where meta-analysis is not possible, a narrative analysis will be conducted using themes derived from the data. For data that allow meta-analysis, a random-effects meta-analysis will be conducted. This systematic review will be reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). Discussion: The study will utilize meta-analysis to establish the anti-inflammatory effects of metformin in GDM, potentially influencing clinical practice and guidelines. Additionally, validating metformin’s anti-inflammatory effects has important implications beyond immediate management of GDM, extending to long-term adverse outcomes for both the mother and the offspring. Systematic review registration: PROSPERO CRD420261337881
- Open Access
- 1 July 2026
- Published by Springer Nature in Research Square
Tracing the Evolution and Circulation of Measles Virus in Africa
Measles remains a significant public health challenge in Africa, threatening global elimination goals. Leveraging the WHO/GMRLN network and sequencing 336 MeV strains, we conducted a comprehensive phylodynamic analysis to reconstruct viral transmission across the continent. African MeV lineages are genetically distinct, circulating in a smooth gradient driven by human mobility rather than isolation. Phylogeographic inference identified at least nine independent intercontinental introductions into Africa between 2008–2018, primarily from Asia (six events), with the Asia-Democratic Republic of the Congo (DRC) corridor showing the highest frequency. Crucially, we quantified extended periods of cryptic transmission (up to 5.13 years in Cameroon) and viral persistence (up to 8.78 years for the Nigeria-to-Cameroon seeding event). Strong correlations link persistence to undetected circulation (r = 0.82) and cases to deaths (r = 0.98). These findings highlight the need for enhanced surveillance and vaccination campaigns to interrupt covert, sustained transmission chains and prevent global dissemination.
- 1 July 2026
- Published by Springer Nature in Research Square
Open AccessTracing the Evolution and Circulation of Measles Virus in Africa
Measles remains a significant public health challenge in Africa, threatening global elimination goals. Leveraging the WHO/GMRLN network and sequencing 336 MeV strains, we conducted a comprehensive phylodynamic analysis to reconstruct viral transmission across the continent. African MeV lineages are genetically distinct, circulating in a smooth gradient driven by human mobility rather than isolation. Phylogeographic inference identified at least nine independent intercontinental introductions into Africa between 2008–2018, primarily from Asia (six events), with the Asia-Democratic Republic of the Congo (DRC) corridor showing the highest frequency. Crucially, we quantified extended periods of cryptic transmission (up to 5.13 years in Cameroon) and viral persistence (up to 8.78 years for the Nigeria-to-Cameroon seeding event). Strong correlations link persistence to undetected circulation (r = 0.82) and cases to deaths (r = 0.98). These findings highlight the need for enhanced surveillance and vaccination campaigns to interrupt covert, sustained transmission chains and prevent global dissemination.
- 15 March 2026
- Published by Wiley in Reviews in Medical Virology
- Vol. 36 (2) , e70138
Towards Ending HIV/AIDS by 2030: Trajectory of Sub‐Saharan Africa—A Post‐COVID‐19 (2019–2024) Review
Globally, the COVID‐19 pandemic perturbed HIV services, jeopardising progress towards the Joint United Nations Programme on HIV/AIDS (UNAIDS) 95–95–95 targets in sub‐Saharan Africa (SSA). This review is an evaluation of sub‐Saharan Africa's progress towards attaining the UNAIDS target of ending HIV/AIDS by the year 2030 in the context of COVID‐19. Data from UNAIDS, the World Health Organisation (WHO), and peer‐reviewed literature were analysed to assess HIV service delivery in SSA from 2019 to 2024, with special attention to regional disparities and health system adaptations before, during, and after the pandemic. Before the COVID‐19 pandemic, Southern and Eastern Africa were nearing the 90–90–90 goals while West and Central Africa made slower progress because of weaker health systems and other situational challenges. Between 2020 and 2022, lockdowns and service disruptions reduced HIV testing, delayed the start of antiretroviral therapy (ART), and led to fewer viral load analyses. To adapt, health systems provided ART for longer periods, offered more community‐based care, expanded health worker roles, and used digital tools to maintain services, especially where infrastructure was strong. By 2023 and 2024, most countries in Southern and Eastern Africa were closer to achieving the 95–95–95 targets, while West and Central Africa continued to recover more slowly. The pandemic revealed both strengths and weaknesses in the HIV response in sub‐Saharan Africa. Institutionalising innovations developed during the pandemic and addressing persistent regional disparities, which reflect uneven progress across the sub‐region, are essential to sustaining progess and achieving epidemic control by 2030.
- 15 March 2026
- Published by Wiley in Reviews in Medical Virology
- Vol. 36 (2) , e70138
Towards Ending HIV/AIDS by 2030: Trajectory of Sub‐Saharan Africa—A Post‐COVID‐19 (2019–2024) Review
Globally, the COVID‐19 pandemic perturbed HIV services, jeopardising progress towards the Joint United Nations Programme on HIV/AIDS (UNAIDS) 95–95–95 targets in sub‐Saharan Africa (SSA). This review is an evaluation of sub‐Saharan Africa's progress towards attaining the UNAIDS target of ending HIV/AIDS by the year 2030 in the context of COVID‐19. Data from UNAIDS, the World Health Organisation (WHO), and peer‐reviewed literature were analysed to assess HIV service delivery in SSA from 2019 to 2024, with special attention to regional disparities and health system adaptations before, during, and after the pandemic. Before the COVID‐19 pandemic, Southern and Eastern Africa were nearing the 90–90–90 goals while West and Central Africa made slower progress because of weaker health systems and other situational challenges. Between 2020 and 2022, lockdowns and service disruptions reduced HIV testing, delayed the start of antiretroviral therapy (ART), and led to fewer viral load analyses. To adapt, health systems provided ART for longer periods, offered more community‐based care, expanded health worker roles, and used digital tools to maintain services, especially where infrastructure was strong. By 2023 and 2024, most countries in Southern and Eastern Africa were closer to achieving the 95–95–95 targets, while West and Central Africa continued to recover more slowly. The pandemic revealed both strengths and weaknesses in the HIV response in sub‐Saharan Africa. Institutionalising innovations developed during the pandemic and addressing persistent regional disparities, which reflect uneven progress across the sub‐region, are essential to sustaining progess and achieving epidemic control by 2030.
- Open Access
- 26 March 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (3) , e0319774
The impact of software and criteria on the selection of best-fit nucleotide substitution models for molecular evolutionary genetic analysis
The statistical selection of best-fit models of nucleotide substitution for multiple sequence alignments (MSAs) is routine in phylogenetics. Our analysis of model selection across three widely used phylogenetic programs (jModelTest2, ModelTest-NG, and IQ-TREE) demonstrated that the choice of program did not significantly affect the ability to accurately identify the true nucleotide substitution model. This finding indicates that researchers can confidently rely on any of these programs for model selection, as they offer comparable accuracy without substantial differences. However, our results underscore the critical impact of the information criterion chosen for model selection. BIC consistently outperformed both AIC and AICc in accurately identifying the true model, regardless of the program used. This observation highlights the importance of carefully selecting the information criterion, with a preference for BIC, when determining the best-fit model for phylogenetic analyses. This study provides an assessment of popular model selection programs while contributing to the advancement of more robust statistical methods and tools for accurately identifying the most suitable nucleotide substitution models.
- 26 March 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (3) , e0319774
Open AccessThe impact of software and criteria on the selection of best-fit nucleotide substitution models for molecular evolutionary genetic analysis
The statistical selection of best-fit models of nucleotide substitution for multiple sequence alignments (MSAs) is routine in phylogenetics. Our analysis of model selection across three widely used phylogenetic programs (jModelTest2, ModelTest-NG, and IQ-TREE) demonstrated that the choice of program did not significantly affect the ability to accurately identify the true nucleotide substitution model. This finding indicates that researchers can confidently rely on any of these programs for model selection, as they offer comparable accuracy without substantial differences. However, our results underscore the critical impact of the information criterion chosen for model selection. BIC consistently outperformed both AIC and AICc in accurately identifying the true model, regardless of the program used. This observation highlights the importance of carefully selecting the information criterion, with a preference for BIC, when determining the best-fit model for phylogenetic analyses. This study provides an assessment of popular model selection programs while contributing to the advancement of more robust statistical methods and tools for accurately identifying the most suitable nucleotide substitution models.
- Open Access
- 18 May 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (5) , e0284210
Identification of some bioactive compounds from Trignonella foenumgraecum as possible inhibitors of PPARϒ for diabetes treatment through molecular docking studies, pharmacophore modelling and ADMET profiling: An in-silico study
Oral antidiabetic agents including the peroxisome proliferator-activated receptor gamma (PPARγ) agonists are available for the clinical management of diabetes mellitus (DM) but most are characterized by many adverse effects. In this study, we explore the antidiabetic properties of phytoconstituents from Trigonellafeonumgraecum (Fabaceae) as potential agonist of PPARγ; using in silico molecular docking, molecular mechanics generalized surface area (MM/GBSA)free binding energy prediction, Pharmacophore modeling experiment, and Pharmacokinetic/ toxicity analysis. One hundred and forty (140) compounds derived from Trigonellafeonumgraecum were screened by molecular docking against protein target PDB 3VI8. Results obtained from binding affinity (BA) and that of binding free energy (BFE) revealed five 5 compounds; arachidonic acid (CID_10467, BA -10.029, BFE -58.9), isoquercetin (CID_5280804, BA -9.507kcal/mol, BFE -56.33), rutin (CID_5280805, BA -9.463kcal/mol, BFE -56.33), quercetin (CID_10121947, BA -11.945kcal/mol, BFE -45.89) and (2S)-2-[[4-methoxy-3-[(pyrene-1-carbonylamino)methyl]phenyl]methyl]butanoic acid (CID_25112371, BA -10.679kcal/mol, BFE -45.73); and were superior to the standard; Rosiglitazone with a docking score of -7.672. Hydrogen bonding was notable in the protein-ligand complex interaction, with hydrophobic bond, polar bond and pipi stacking also observed. Their Pharmacokinetic/ toxicity profile showed varying druggable characteristics, but; arachidonic acid had the most favorable characteristics. These compounds are potential agonists of PPARγ and are considered as antidiabetic agents after successful experimental validation.
- 18 May 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (5) , e0284210
Open AccessIdentification of some bioactive compounds from Trignonella foenumgraecum as possible inhibitors of PPARϒ for diabetes treatment through molecular docking studies, pharmacophore modelling and ADMET profiling: An in-silico study
Oral antidiabetic agents including the peroxisome proliferator-activated receptor gamma (PPARγ) agonists are available for the clinical management of diabetes mellitus (DM) but most are characterized by many adverse effects. In this study, we explore the antidiabetic properties of phytoconstituents from Trigonellafeonumgraecum (Fabaceae) as potential agonist of PPARγ; using in silico molecular docking, molecular mechanics generalized surface area (MM/GBSA)free binding energy prediction, Pharmacophore modeling experiment, and Pharmacokinetic/ toxicity analysis. One hundred and forty (140) compounds derived from Trigonellafeonumgraecum were screened by molecular docking against protein target PDB 3VI8. Results obtained from binding affinity (BA) and that of binding free energy (BFE) revealed five 5 compounds; arachidonic acid (CID_10467, BA -10.029, BFE -58.9), isoquercetin (CID_5280804, BA -9.507kcal/mol, BFE -56.33), rutin (CID_5280805, BA -9.463kcal/mol, BFE -56.33), quercetin (CID_10121947, BA -11.945kcal/mol, BFE -45.89) and (2S)-2-[[4-methoxy-3-[(pyrene-1-carbonylamino)methyl]phenyl]methyl]butanoic acid (CID_25112371, BA -10.679kcal/mol, BFE -45.73); and were superior to the standard; Rosiglitazone with a docking score of -7.672. Hydrogen bonding was notable in the protein-ligand complex interaction, with hydrophobic bond, polar bond and pipi stacking also observed. Their Pharmacokinetic/ toxicity profile showed varying druggable characteristics, but; arachidonic acid had the most favorable characteristics. These compounds are potential agonists of PPARγ and are considered as antidiabetic agents after successful experimental validation.
- Open Access
- 15 September 2022
- Published by MDPI AG in Preprints.org
Potential Inhibitors of EGFR Tyrosine Kinase from Scutellaria baicalensis: A Cheminformatics and Molecular Docking Studies
Epidermal Growth Factor Receptor (EGFR) tyrosine kinase is a cell surface receptor whose overexpression has been associated with different types of cancers including brain cancer (glioblastoma multiforme). The ability of the extract of Scutellaria baicalensis to inhibit the proliferation of malignant glioma cells have been reported. Thus, in this study we report the identification of 307 bioactive constituents responsible for the anti-glioblastoma multiforme effect from S. baicalensis using in silico studies such as molecular docking, binding free energy calculations, pharmacophore modelling, induced-fit docking, gene enrichment analysis, molecular dynamic simulations and ADMET predictions. A total of 307 chemical constituents of S. baicalensis were screened and the top 10 scoring compounds indicated different binding affinities ranging from -9.010 to -6.427 kcal/mol towards the EGFR tyrosine kinase; Ganhuangenin, 5,7,2',5'-tetrahydroxyflavone, (2R)-2-(2,6-dihydroxyphenyl)-3,4-dihydro-2H-chromene-5,7-diol, and tenaxin I possess higher binding affinities (-9.010 to -8.649 kcal/mol) compared to the standard ligand, erlotinib having -8.539 kcal/mol. The compounds interacted with amino acids of clinical importance such as MET 769, GLU 738, THR 766 via H-bond. The structural features involved in the interaction with the target were mostly two aromatic rings, H-bond donors and acceptors and some hydrophobic interactions which varies between the ligands. Better docking scores in the induced-fit docking further validates the inhibitory potential of the compounds against the flexible protein. All the top-scoring ligands from S. baicalensis had zero Lipinski violation and also obeyed other drug-likeness rules by Ghose, Veber, Egan, and Muegge with the exception of breviscapine. Interestingly, all the compounds are not likely to be hepatotoxic, mutagenic, or cytogenic, making them potentially safe as anti-cancer agents.
- 15 September 2022
- Published by MDPI AG in Preprints.org
Open AccessPotential Inhibitors of EGFR Tyrosine Kinase from Scutellaria baicalensis: A Cheminformatics and Molecular Docking Studies
Epidermal Growth Factor Receptor (EGFR) tyrosine kinase is a cell surface receptor whose overexpression has been associated with different types of cancers including brain cancer (glioblastoma multiforme). The ability of the extract of Scutellaria baicalensis to inhibit the proliferation of malignant glioma cells have been reported. Thus, in this study we report the identification of 307 bioactive constituents responsible for the anti-glioblastoma multiforme effect from S. baicalensis using in silico studies such as molecular docking, binding free energy calculations, pharmacophore modelling, induced-fit docking, gene enrichment analysis, molecular dynamic simulations and ADMET predictions. A total of 307 chemical constituents of S. baicalensis were screened and the top 10 scoring compounds indicated different binding affinities ranging from -9.010 to -6.427 kcal/mol towards the EGFR tyrosine kinase; Ganhuangenin, 5,7,2',5'-tetrahydroxyflavone, (2R)-2-(2,6-dihydroxyphenyl)-3,4-dihydro-2H-chromene-5,7-diol, and tenaxin I possess higher binding affinities (-9.010 to -8.649 kcal/mol) compared to the standard ligand, erlotinib having -8.539 kcal/mol. The compounds interacted with amino acids of clinical importance such as MET 769, GLU 738, THR 766 via H-bond. The structural features involved in the interaction with the target were mostly two aromatic rings, H-bond donors and acceptors and some hydrophobic interactions which varies between the ligands. Better docking scores in the induced-fit docking further validates the inhibitory potential of the compounds against the flexible protein. All the top-scoring ligands from S. baicalensis had zero Lipinski violation and also obeyed other drug-likeness rules by Ghose, Veber, Egan, and Muegge with the exception of breviscapine. Interestingly, all the compounds are not likely to be hepatotoxic, mutagenic, or cytogenic, making them potentially safe as anti-cancer agents.
- Open Access
Epidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa
COVID-19 disease dynamics have been widely studied in different settings around the globe, but little is known about these patterns in the African continent. To investigate the epidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa, more than 2400 complete genomes from 33 African countries were retrieved from the GISAID database and analyzed. We investigated their diversity using various clade and lineage nomenclature systems, reconstructed their evolutionary divergence and history using maximum likelihood inference methods, and studied the case and death trends in the continent. We also examined potential repeat patterns and motifs across the sequences. In this study, we show that after almost one year of the COVID-19 pandemic, only 143 out of the 782 Pango lineages found worldwide circulated in Africa, with five different lineages dominating in distinct periods of the pandemic. Analysis of the number of reported deaths in Africa also revealed large heterogeneity across the continent. Phylogenetic analysis revealed that African viruses cluster closely with those from all continents but more notably with viruses from Europe. However, the extent of viral diversity observed among African genomes is closest to that of the Oceania outbreak, most likely due to genomic under-surveillance in Africa. We also identified two motifs that could function as integrin-binding sites and N-glycosylation domains. These results shed light on the evolutionary dynamics of the circulating viral strains in Africa, elucidate the functions of protein motifs present in the genome sequences, and emphasize the need to expand genomic surveillance efforts in the continent to better understand the molecular, evolutionary, epidemiological, and spatiotemporal dynamics of the COVID-19 pandemic in Africa.
Open AccessEpidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa
COVID-19 disease dynamics have been widely studied in different settings around the globe, but little is known about these patterns in the African continent. To investigate the epidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa, more than 2400 complete genomes from 33 African countries were retrieved from the GISAID database and analyzed. We investigated their diversity using various clade and lineage nomenclature systems, reconstructed their evolutionary divergence and history using maximum likelihood inference methods, and studied the case and death trends in the continent. We also examined potential repeat patterns and motifs across the sequences. In this study, we show that after almost one year of the COVID-19 pandemic, only 143 out of the 782 Pango lineages found worldwide circulated in Africa, with five different lineages dominating in distinct periods of the pandemic. Analysis of the number of reported deaths in Africa also revealed large heterogeneity across the continent. Phylogenetic analysis revealed that African viruses cluster closely with those from all continents but more notably with viruses from Europe. However, the extent of viral diversity observed among African genomes is closest to that of the Oceania outbreak, most likely due to genomic under-surveillance in Africa. We also identified two motifs that could function as integrin-binding sites and N-glycosylation domains. These results shed light on the evolutionary dynamics of the circulating viral strains in Africa, elucidate the functions of protein motifs present in the genome sequences, and emphasize the need to expand genomic surveillance efforts in the continent to better understand the molecular, evolutionary, epidemiological, and spatiotemporal dynamics of the COVID-19 pandemic in Africa.